LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Trial Profile

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Darapladib (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STABILITY
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 May 2017 Results assessing the relation between visit-to-visit variability of blood pressure and cardiovascular risk in patients with stable coronary heart disease published in the European Heart Journal.
    • 16 Nov 2016 Results of visit-to-visit variability in blood pressure presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top